Phase 3 randomized placebo-controlled study of fezolinetant for hot flashes in women with hormone receptor-positive breast cancer receiving adjuvant endocrine therapy

Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Fezolinetant with Placebo (2 arms). Primary endpoints: Change in frequency of moderate to severe vasomotor symptoms from baseline to week 4, Change in frequency of moderate to severe vasomotor symptoms from baseline to week 12 and 2 more. Planned start Jan 2025; status: authorised.